Clinical trials: Flu
COVID-19 Respiratory Infection, FLU
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
The primary objective of this study is to determine the safety and efficacy profile of the food supplement (KUNAMIN®) containing grape juice, seed, stem, and bark given to patients treated with the established treatment regimen…
- Conditions
- COVID-19 Respiratory Infection, FLU, Cold; Influenza, Bacterial Pneumonia
- Trial name
- NCT05417997
- Testing
- Kunamin®, Favipiravir, Enoxaparin
- Where
- Turkey (Türkiye)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- RAAS Nutritionals, LLC
Healthy Volunteers
Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine
This project is a pilot safety and immunogenicity study of transcutaneous vaccination with live attenuated Listeria monocytogenes BMB72 bacteria (actA/plcB-deleted, expressing influenza A nucleoprotein) and a cutaneous adjuvant…
- Trial name
- NCT01311817
- Testing
- BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Influenza
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
- Trial name
- NCT07496450
- Testing
- mRNA-1018-H5
- Where
- 35 sites in United States, United Kingdom
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza Vaccine in Scleroderma
Influenza Vaccination in Patients With Scleroderma
The safety and efficacy of vaccination against influenza in patients with scleroderma is not clear. The objective of this study is to assess its safety and efficacy in 50 patients with scleroderma in comparison with 30 controls
- Trial name
- NCT01002508
- Testing
- Influenza vaccine
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Influenza Disease; Flu
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 < 50 years.
- Trial name
- NCT00264576
- Testing
- Influenza Virus Vaccine
- Where
- 4 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Vaccination Uptake, Knowledge
Enhancing Maternal Vaccine Knowledge and Uptake: The InTroDuce-Programme Trial
The goal of this InTroDuce-Programme interventional trial aims to test whether a web-based educational program can improve pregnant women's knowledge about Influenza and Tdap vaccinations and increase their intention to get…
- Conditions
- Vaccination Uptake, Knowledge, Tetanus, Diphtheria and Acellular Pertussis Vaccination, Influenza
- Trial name
- NCT06815250
- Testing
- Influenza and Tdap Vaccination Educational and Learning Module
- Where
- 4 sites in Malaysia
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
Influenza Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
This study will evaluate the immunogenicity and safety of GSK Biologicals' Trivalent split virion influenza vaccine Fluviral for the 2008-2009 season in adults over the age of 18.
- Trial name
- NCT00718120
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, Vaccination; Infection
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old
Comparative trial of tolerability, reactogenicity, safety and immunogenicity of the Flu-M vaccine as compared to the Vaxigrip® vaccine in terms of prevention of influenza in children aged 6 months to 9 years (at the time of the…
- Conditions
- Influenza, Human, Vaccination; Infection, Vaccines
- Trial name
- NCT05470582
- Testing
- Flu-M, Inactivated split influenza vaccine 0.5 mL, Vaxigrip, Inactivated split influenza vaccine 0.5 mL, Flu-M, Inactivated split influenza vaccine 0.25 mL
- Where
- 2 sites in Russia
- Volunteers
- 1,066 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Chronic Kidney Disease Requiring Chronic Dialysis, Vaccine Response
Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination
The aim of this observational study is to determine if and how kidney failure affects the development of protective immune responses following vaccination in patients on chronic dialysis.
- Trial name
- Tfh-CKD (NCT06635525)
- Testing
- Influenza vaccination, SARS-CoV-2 vaccine
- Where
- 3 sites in Italy
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza A Virus, H1N1 Subtype
Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.
This project may help to answer several fundamental questions related to public health regarding vaccination against influenza viruses and regarding the influenza A(H1N1)v pandemy: What is the immunologic efficacy in terms of…
- Trial name
- FLU-HOP (NCT01063608)
- Testing
- Anti-H1N1v Vaccine
- Where
- 2 sites in France
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years
This phase I/II, randomized, modified double-blind, multi-center study assessed the safety and immunogenicity of a high-dose Quadrivalent influenza vaccine (QIV-HD) in older adults (greater than or equal to [>=] 65 years).
- Trial name
- NCT03233217
- Testing
- QIV-HD by IM, QIV-SD by SC, QIV-HD by SC
- Where
- 2 sites in Japan
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
To provide serum to the Food and Drug Administration (FDA) for use by FDA, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) for characterization of circulating influenza strains.
- Trial name
- NCT00258817
- Testing
- Influenza Virus Vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human, Influenza
Mail Outreach To Increase Vaccination Acceptance Through Engagement
The aim of this study is to determine whether receiving a core letter signed by the Surgeon General or the Director of the National Vaccine Program that provides only information about influenza, or a core letter signed by the…
- Conditions
- Influenza, Human, Influenza, Human Flu
- Trial name
- MOTIVATE (NCT02243774)
- Testing
- Core letter signed by Surgeon General, Core letter signed by the Director of the National Vaccine Program, Core letter signed by Surgeon General + implementation prompt
- Where
- United States
- Volunteers
- 228,000 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Flu, Human
Factors Influencing Flu Vaccination in Primary Health Care
This study aims to study the barriers to flu vaccination among at-risk people at the Primary Health Care level in order to increase the vaccination rates as recommended by the World Health Organization.
- Trial name
- FIVA (NCT04097197)
- Testing
- Brief educational intervention
- Where
- Portugal
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Agrupamento de Centros de Saúde de Dão Lafões
Influenza
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone® (TIV) in children 6 to 35 months of age.
- Trial name
- NCT01974895
- Testing
- FluLaval® Quadrivalent, Fluzone®
- Where
- 12 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset) following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs, in healthy…
- Trial name
- NCT00306527
- Testing
- Cell culture derived influenza vaccine, egg-derived influenza subunit vaccine
- Where
- 5 sites in Poland
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine
Studies have shown that a broader spectrum influenza vaccine may help in reducing the influenza burden of disease. Butantan Institute is currently developing a quadrivalent influenza vaccine candidate.
- Trial name
- NCT03927131
- Testing
- QIV-IB, TIVV-IB, TIVY-IB
- Where
- 12 sites in Brazil
- Volunteers
- 5,822 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
2009 H1N1 Influenza
Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children
A total of 51 children between the ages of 4 and 9 will be randomized to receive a two dose schedule of either licensed live attenuated A/California/07/09 influenza vaccine (LAIV) or licensed inactivated A/California/07/09…
- Trial name
- H1N1Children (NCT01097941)
- Testing
- Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
An open-label, dose-ranging influenza challenge study in healthy adult volunteers to determine the optimal infection dose and safety of a recombinant H3N2 (A/Texas/ A/Texas/71/2017 (H3N2, clade 3C3a) influenza strain.
- Trial name
- NCT04978454
- Testing
- Influenza RG-A/Texas/71/2017 (H3N2) Challenge
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.